Index of Articles From HIV i-Base

About HIV i-Base

Articles | Booklets | HIV Treatment Bulletin

HIV i-Base logo

Articles

Avoiding and Managing Side Effects (May 2008)
Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)

Booklets

An Introduction to Combination Therapy (PDF) (July 2010)
An easy-to-read guide from the United Kingdom on what questions to ask, how to talk to your doctor, and the difference between various anti-HIV drugs and combinations.
Hepatitis C for People Living With HIV (March 2009)
Testing, coinfection, treatment and support.
To read PDF, click here.
Guide to HIV, Pregnancy and Women's Health (January 2009)
To read PDF, click here.

HIV Treatment Bulletin

FDA Approve New NNRTI Rilpivirine (Edurant) in the U.S. (July/August 2011)
To read PDF, click here.
FDA Approve New NNRTI-Based Fixed-Dose Combination of Rilpivirine/Tenofovir/FTC (Complera) in the U.S. (July/August 2011)
To read PDF, click here.
FDA Approve Boceprevir (Victrelis) for HCV (July/August 2011)
To read PDF, click here.
FDA Approve Telaprevir (Incivek) to Treat Hepatitis C (July/August 2011)
To read PDF, click here.
FDA Supplemental Information About Using Boceprevir and Telaprevir (July/August 2011)
To read PDF, click here.
Dolutegravir (S/GSK1349572) With Multivitamins or Acid Reducing Agents (July/August 2011)
To read PDF, click here.
Lopinavir and Rifampicin Interaction in HIV-Positive Patients (July/August 2011)
To read PDF, click here.
Case Reports: Cushing's Syndrome With Atazanavir/Ritonavir (July/August 2011)
To read PDF, click here.
Gilead Signs Up for Medicines Patent Pool (July/August 2011)
To read PDF, click here.
FDA Approval of Generic ARVs (July/August 2011)
To read PDF, click here.
HPTN 052 Study Stopped Early: Significant Reduction in HIV Transmission From Early Use of HIV Treatment in Serodifferent Partners (July/August 2011)
To read PDF, click here.
Treatment in Seroconversion Maintains HIV-Specific Immune Responses Similar to Long-Term Slow Progressors (July/August 2011)
To read PDF, click here.
Monitoring Treatment in Resource-Limited Settings: Results From PHPT-3 and Stratall ANRS12110/ESTER Trials (July/August 2011)
To read PDF, click here.
DART: High Rates of Viral Suppression After Five Years and a Single CD4 Test With a Threshold of 250 Cells/mm³ Could Reduce Unnecessary Switching (July/August 2011)
To read PDF, click here.
Lopinavir/r Monotherapy Used as Second-Line Therapy in Resource-Limited Settings (July/August 2011)
To read PDF, click here.
Treating Children Previously Exposed to Single Dose Nevirapine: Update on IMPAACT P1060 and NEVEREST (July/August 2011)
To read PDF, click here.
Lopinavir/Ritonavir Oral Solution Toxicity in Neonates (July/August 2011)
To read PDF, click here.
Paediatric Antiretroviral Pipeline: Darunavir and Raltegravir (July/August 2011)
To read PDF, click here.
Pharmacokinetics of Different Rifabutin Dosing Strategies With Lopinavir/Ritonavir-Based ART (July/August 2011)
To read PDF, click here.
Initiation of ART During Breastfeeding Can Induce Multidrug Resistance in Infants (July/August 2011)
To read PDF, click here.
Webcasts for Major Research at IAS 2011 (July/August 2011)
To read PDF, click here.
Treatment Is Prevention: ARV Treatment in HPTN-052 Reduces Transmission by at Least 96%: Single Transmission in Treatment Arm Occurred Prior to Viral Suppression (July/August 2011)
To read PDF, click here.
Daily Oral Tenofovir/FTC PrEP Reduces Heterosexual Transmission by 63% in the TDF2 Study (July/August 2011)
To read PDF, click here.
Tenofovir/FTC vs. Tenofovir as Daily Oral PrEP: Preliminary Results From Partners PrEP (July/August 2011)
To read PDF, click here.
Elvitegravir vs. Raltegravir: 48-Week Results in Treatment-Experienced Patients (July/August 2011)
To read PDF, click here.
Dolutegravir: 48-Week Results From Phase II Study in Treatment-Naive Patients (July/August 2011)
To read PDF, click here.
Lersivirine: 48-Week Results Compared to Efavirenz in Phase 2 Treatment-Naive Study (July/August 2011)
To read PDF, click here.
Maraviroc Plus Atazanavir/r Without Nukes Versus Standard of Care: 48-Week Results (July/August 2011)
To read PDF, click here.
SPARTAC Trial: Treatment in Primary Infection for 48 Weeks Shows Small Delay in Disease Progression (July/August 2011)
To read PDF, click here.
Hearing Loss Not Associated With HIV in MACS and WIHS Cohorts (July/August 2011)
To read PDF, click here.
Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy (July/August 2011)
To read PDF, click here.
Low Birth Weight and Preterm Delivery (July/August 2011)
To read PDF, click here.
Hormonal Contraception and HIV Transmission Risk (July/August 2011)
To read PDF, click here.
No Difference in AIDS-Free Survival in Children Starting ART With a CD4% Between 15%-24% Compared to Deferring Until Less Than 15% in the PREDICT Trial (July/August 2011)
To read PDF, click here.
Paediatric Antiretroviral Pipeline: Update on Etravirine and Maraviroc (July/August 2011)
To read PDF, click here.
Prematurity Not Associated With Early Mortality in Infants on ART (July/August 2011)
To read PDF, click here.
More Metabolic Abnormalities in Children Receiving a PI Compared to NNRTI in NEVEREST Study (July/August 2011)
To read PDF, click here.
Free Online Resource for Treatment Decisions Without Access to Genotype Resistance Tests (July/August 2011)
To read PDF, click here.
Quad Reduces Levels of Oral Contraceptives (May/June 2011)
To read PDF, click here.
Elvitegravir/Cobicistat and Acid Reducing Agents (May/June 2011)
To read PDF, click here.
Lopinavir/r Reduces Levels of Rifabutin (May/June 2011)
To read PDF, click here.
Cobicistat Has Little Impact on CYP2D6 and CYP2B6 (May/June 2011)
To read PDF, click here.
Atazanavir Levels Indicate Need for Higher Dose During Pregnancy (May/June 2011)
To read PDF, click here.
Once-Daily 150-mg Maraviroc Explored in People Taking Atazanavir/Ritonavir (May/June 2011)
To read PDF, click here.
Lopinavir Troughs Lower in Children on Once-Daily Dose With Efavirenz (May/June 2011)
To read PDF, click here.
Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily (May/June 2011)
To read PDF, click here.
Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily (May/June 2011)
To read PDF, click here.
Atazanavir in Pregnancy: 155 Cases in London Clinics (May/June 2011)
To read PDF, click here.
Co-Morbidity and Late Presentation -- Findings From an Over 50s Cohort (May/June 2011)
To read PDF, click here.
Health Outcomes for Young Adults With Perinatally Acquired HIV Infection Following Transfer to Adult Services (May/June 2011)
To read PDF, click here.
The Use of Calcaneal Stiffness Index to Screen for Osteoporosis in HIV-Infected Individuals (May/June 2011)
To read PDF, click here.
Frequency and Characteristics of Long-Term Non-Progressors and HIV Controllers in the Chelsea and Westminster Cohort (May/June 2011)
To read PDF, click here.
Cerebral Function in Perinatally HIV Infected Young People and HIV Uninfected Sibling Controls (May/June 2011)
To read PDF, click here.
An Audit of HIV Care Provision for Immigration Removal Centre (May/June 2011)
To read PDF, click here.
BASHH/BHIVA PEPSE Guidelines for Comment (May/June 2011)
To read PDF, click here.
UK National Guideline on Safer Sex Advice (May/June 2011)
To read PDF, click here.
Rapid Report: State of HCV Policy, Treatment, Access (May/June 2011)
To read PDF, click here.
Inflammation and Intervention: How Does HIV Cause AIDS and How Does It Cause Disease Despite ART (May/June 2011)
To read PDF, click here.
When to Start ART in Patients Co-Infected With TB: Results From Two Trials Presented at CROI (May/June 2011)
To read PDF, click here.
First Workshop on Nanomedicine for Infectious Diseases of Poverty, 27–31 March 2011, Magaliesberg, South Africa (May/June 2011)
To read PDF, click here.
London HIV Consortium Issues New Guidelines for ARV Prescribing (March/April 2011)
To read PDF, click here.
European Medicines Agency Issues Restricted Indication for d4T (Stavudine) (March/April 2011)
To read PDF, click here.
Changes to Starting Dose of Saquinavir in Naive Patients (March/April 2011)
To read PDF, click here.
FDA Approves Nevirapine XR (March/April 2011)
To read PDF, click here.
Lopinavir/r Oral Solution (March/April 2011)
To read PDF, click here.
Atazanavir Use During Pregnancy (March/April 2011)
To read PDF, click here.
Nelfinavir Interaction With Warfarin (March/April 2011)
To read PDF, click here.
New Antiretrovirals: Dolutegravir, Entry Inhibitor (BMS-663068) and Tenofovir Pro-Drug (GS-7340) (March/April 2011)
To read PDF, click here.
Immune-Based Treatment Increases HIV-Resistant CD4 Cells in Phase 1 Study (March/April 2011)
To read PDF, click here.
Antiretroviral Prevention: Oral PrEP, Gels and Treatment Studies (March/April 2011)
To read PDF, click here.
Further Efficacy Analyses From the iPrEx Study (March/April 2011)
To read PDF, click here.
Topical Gels as PEP and PrEP: Animal and Human Studies (March/April 2011)
To read PDF, click here.
Maternal Risk Following Short Course HAART (March/April 2011)
To read PDF, click here.
Pre-Term Delivery and HAART (March/April 2011)
To read PDF, click here.
HAART More Effective Than AZT Monotherapy in the Botswana PMTCT Programme (March/April 2011)
To read PDF, click here.
Lopinavir/r Monotherapy for PMTCT (March/April 2011)
To read PDF, click here.
No Evidence of Increased Risk of MTCT With Sequential Pregnancies in UK and Ireland (March/April 2011)
To read PDF, click here.
Recently Infected Women at the Time of Delivery Have a Higher Rate of In-Utero Transmission in PEPI-Malawi (March/April 2011)
To read PDF, click here.
Reduced CCL22 Concentrations in Cervicovaginal Secretions From Pregnant Women (March/April 2011)
To read PDF, click here.
First Results From Telaprevir in HIV/HCV Coinfection (March/April 2011)
To read PDF, click here.
HCV Reinfection Rates in HIV-Positive Gay Men (March/April 2011)
To read PDF, click here.
Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (November/December 2008)

My Health Tracker

Assess Your Risk for HIV

U.S. ASO Finder

Find a Therapist

What Really Fuels the HIV/AIDS Epidemic in Black America?

Top 10 HIV/AIDS-Related Clinical Developments of 2011

Ten HIV/AIDS Stories that Defined 2011

The Culture War in the Black HIV/AIDS Movement Is Hurting Us All

Tennessee Senator: It's Virtually Impossible for Heterosexuals to Contract HIV From Sex: A Blog Entry by Kellee Terrell

More >>

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.